Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.
China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC)
China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.
Teva pulls fremanezumab cluster headaches trial
Teva pulls fremanezumab cluster headaches trial
Teva is discontinuing a late-stage trial assessing the efficacy of its experimental anti-CGRP therapy fremanezumab in reducing cluster headaches.
Large international study links blood vitamin D levels to colorectal cancer risk
Large international study links blood vitamin D levels to colorectal cancer risk
A new study authored by scientists from the American Cancer Society, the Harvard T.
MS: New findings may 'prevent future loss of brain cells'
MS: New findings may 'prevent future loss of brain cells'
Blocking a unique type of cell death that occurs in multiple sclerosis could be a way to halt the debilitating disease, according to new research.
Orion Biotechnology Canada Acquires K2Biomedical
Orion Biotechnology Canada Acquires K2Biomedical
OTTAWA, June 14, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd.
Modern alchemists are making chemistry greener
Modern alchemists are making chemistry greener
Ancient alchemists tried to turn lead and other common metals into gold and platinum.
Despite FDA hold, Epizyme’s tazemetostat posts positive interim data
Despite FDA hold, Epizyme’s tazemetostat posts positive interim data
Epizyme plans for file an NDA for tazemetostat in epithelioid sarcoma, a molecularly defined solid tumor, by the end of the year.
vTv's Alzheimer's drug azeliragon flops in phase 3 again
vTv's Alzheimer's drug azeliragon flops in phase 3 again
The data are in from another phase 3 trial of vTv Therapeutics’ Alzheimer’s drug azeliragon and they’re not pretty—it missed a pair of coprimary endpoints, failing to improve cognitive or fun...
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
ViiV Healthcare today announced positive headline results from its phase III GEMINI study programme.
Lilly's lupus treatment succeeds in mid-stage trial
Lilly's lupus treatment succeeds in mid-stage trial
(Reuters) - Eli Lilly & Co said on Wednesday its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this...
Is Parkinson's linked to bacteriophages?
Is Parkinson's linked to bacteriophages?
A recent study concludes that bacteriophages — or viruses that attack bacteria — may play a pivotal role in the development of Parkinson's disease.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand